The food additive carrageenan (E 407) can be responsible for the development of chronic inflammatory bowel disease, ulcers, and increased blood sugar levels in animals. Researchers have now ...

The food additive carrageenan (E 407) can be responsible for the development of chronic inflammatory bowel disease, ulcers, ...

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial ...

The Far West Local Health District (FWLHD) has inaugurated a dedicated chronic and complex wound and stoma care clinic at ...

The food additive carrageenan (E 407) can be responsible for the development of chronic inflammatory bowel disease, ulcers, and increased blood sugar levels in animals. DZD researchers have now ...

These risks increased with the number of prescriptions, the authors emphasized. For example, hazard ratios for patients with ...

VVeno Medical's NVNO submission of the final module for VenoValve’s Premarket Approval (PMA) application to the FDA represents a crucial milestone in addressing unmet needs in the treatment of Chronic ...

Researchers at the University of Pittsburgh are developing a new wound treatment product aimed at reducing the need for ...

A new federal payment policy will sharply reduce the number of specialty wound care products available to certain Medicare patients.

The global tissue engineered skin substitute market is projected to grow from USD 2.4 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 3.9%. The rising demand for advanced wound care solutions ...

Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% ...

The Company is also developing a next-generation, non-surgical transcatheter based replacement venous valve called enVVe, which could appeal to an even larger market in terms of both patients and ...